- Details
- Sam Chang is joined by James (Jed) Ferguson to explore disparities in the treatment of muscle-invasive bladder cancer. Dr. Ferguson's team delved into the National Cancer Database, revealing that a significant percentage of patients do not receive aggressive treatments post-TURBT, with factors such as age, comorbidity, race, insurance status, and treatment facility type playing crucial roles in th...
|
- Details
- Sam Chang engages with Arlene Siefker-Radtke to explore the transformative impact of erdafitinib in treating advanced and metastatic urothelial cancer. Dr. Siefker-Radtke illuminates the targeted approach of erdafitinib, emphasizing its efficacy in hitting specific genetic alterations, particularly FGFR3/2 mutations, prevalent in 15-20% of metastatic bladder tumors. Highlighting the drug's journey...
|
- Details
- Ashish Kamat converses with Akshay Sood about the challenging diagnosis and management of non-metastatic plasmacytoid bladder cancer. Dr. Sood elaborates on his comprehensive study published in the Journal of Urology. He highlights the rarity and lethal nature of the plasmacytoid variant, which represents approximately 1% of muscle-invasive bladder cancers. Through a retrospective analysis of 56 p...
|
- Details
- Sam Chang converses with Neal Shore about the KEYNOTE-676 trial, focusing on combining pembrolizumab with BCG for high-risk NMIBC patients previously treated with BCG. This study aims to explore the potential synergy between two immunotherapeutic agents, leveraging pembrolizumab's success in MIBC to improve outcomes in NMIBC. With enrollment progressing well, the trial signals a collaborative futu...
|
- Details
- Sam Chang engages with Roger Li to delve into the TAR-210 study, focusing on bladder-based intravesical therapy targeting FGFR3 in non-muscle invasive bladder cancer (NMIBC) patients. Dr. Li shares insights from the multi-site international study, highlighting the efficacy of Erdafitinib, particularly in patients with FGFR alterations. Despite the challenges with oral Erdafitinib's toxicity, the i...
|
- Details
- Sam Chang and Roger Li delve into a study examining genetic profiles in non-muscle invasive bladder cancer and adjacent benign bladder tissue. Conducted on a cohort of nine patients, the study leveraged whole exome sequencing to explore mutations in both cancerous and non-cancerous tissue samples, uncovering a significant mutation overlap yet a lower mutation count in benign tissues. This investig...
|
- Details
- Sam Chang converses with Matthew Galsky about the ANTICIPATE II trial, examining the combination of APL-1202 (nitroxoline salt) and tislelizumab in treating muscle-invasive bladder cancer. Dr. Galsky discusses APL-1202's journey from an antibiotic with noted anti-cancer properties to a promising cancer treatment due to its immunogenic cell death induction and potential synergy with PD-1 inhibitors...
|
- Details
- Michael Basin presents an analysis on FGFR alterations and the genomic landscape differences between upper and lower tract urothelial carcinoma. Utilizing data from the extensive Foundation Medicine database, which includes around 10,000 bladder cancer patients, Dr. Basin's study focuses on the subset with FGFR mutations. The research reveals that lower tract tumors possess more genomic co-drivers...
|
- Details
- Zachary Klaassen and Stephen Williams delve into the economic and treatment implications of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Dr. Williams, with a collaborative team spanning medical oncology to economic experts, has spent over a decade exploring these treatment pathways, revealing significant cost differences and outcomes through extensive research, in...
|
- Details
- Zach Klaassen and Joshua Meeks discuss the ongoing BCG shortage impacting bladder cancer treatment, tracing its origins back to production issues in 2012 and guideline changes in 2016 that increased BCG demand. They highlight the shift towards using Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its effectiveness and availability. The d...
|
